Abstract: The present invention relates to an ion exchange chromatography process for purifying GLP-1 or an analog or a derivative thereof from a mixture containing said GLP-1 and related impurities, and to an industrial method including such ion exchange chromatography process.

Abstract: The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the said polypeptide; vector derived the said DNA; host cells transformed the said vector; antibody of the said polypeptide; pharmaceutical composition containing the said peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the said protein p140; agent for the prevention and/or treatment for the currently said the prevention and/or treatment method; agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylation of protein p140, as active ingredient and the screening methods of the said prevention and/or treatment agent. Tyrosine phosphorylation of protein p140 is an essential step in the induction of hypoglycemia by glucose uptake.

Abstract: The present invention relates to methods and compositions for the treatment of biological disorders regulatable by the controlled expression or inhibition of the described NUCPs.

Abstract: The present invention, which is based on the discovery of novel genes encoding rp polypeptides, features therapeutics, diagnostics and screening assays.

Abstract: The present invention provides a purified and isolated nucleic acid encoding a sodium/iodide symporter. The present invention also provides purified sodium/iodide symporter, a vector comprising nucleic acid encoding sodium/iodide symporter, a host cell transformed with the vector, and a method for producing recombinant sodium/iodide symporter. In addition, the present invention provides nucleic acid probes and mixtures thereof specific for sodium/iodide symporter nucleic acid and antibodies immunoreactive with sodium/iodide symporter. The present invention also provides a method for diagnosing and treating thyroid disorders associated with non-functional sodium/iodide symporter. Furthermore, the present invention provides a method for the selective ablation of tissue. The present invention also provides a method for identifying an iodide transport protein in non-thyroid tissue. Finally, the present invention provides a non-human, transgenic model for a thyroid disorder.

Abstract: The present invention concerns muteins of avidin and streptavidin with a reduced binding affinity for biotin as well as their use as interference elimination reagents in methods for the determination of an analyte e.g. in diagnostic tests such as for example immunoassays and nucleic acid hybridization assays. In addition the invention concerns the use of muteins of avidin and streptavidin as systems capable of regeneration for binding biotin e.g. for the analysis of biotinylated molecules, for examining receptor ligand interactions as well as for the affinity purification of biotinylated molecules.

Abstract: The invention provides seven human Ras proteins (RASP) and polynucleotides which identify and encode RASP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of RASP.

Abstract: This invention relates to the gene sequence of a novel transcription factor specific for central 5-HT (serotonergic) neurons. The sequence and products are useful in screening methods for identifying and testing agonists and antagonists of seronergic activity.

Abstract: Novel polynucleotides including partial and extended sequences, and open reading frames, are provided, together with probes and primers, DNA constructs comprising the polynucleotides, biological materials and organisms incorporating the polynucleotides, polypeptides expressed by the polynucleotides, and methods for using the polynucleotides and polypeptides.

Abstract: The invention concerns the use of a coiled coil protein which is capable of forming a homodimer which dissociates into monomers on change of temperature, in a method of isolating a ligand or desired protein from a sample. A method of isolating a ligand which binds to the coiled coil protein is described as well as methods of isolating a desired protein which is tagged with a coiled coil protein or a ligand which binds to a coiled coil protein, or is tagged with a coiled coil protein monomer.

Abstract: Compounds and methods are described for producing streptavidin mutants with changed affinities. In particular, modifications to the sequence of the natural streptavidin gene is described to create amino acid substitutions resulting in greater affinity for biotin substitutes than for biotin.

Abstract: The invention relates to the new use of Serum Amyloid P component (SAP) and/or endotoxin-binding fragments thereof for the preparation of a pharmaceutical composition for neutralizing lipopolysaccharide and particularly for the treatment of sepsis. The invention further relates to a diagnostic method for demonstrating the presence of endotoxin in blood or blood fractions, such as serum or plasma.

Abstract: The present invention provides a cyclic peptide comprising the structure: wherein X is selected from the group consisting of an amino acid, an amino acid analog, a peptidomimetic and a non-amide isostere, Z is selected from the group consisting of a synthetic amino acid and a biosynthetic amino acid, R is selected from the group consisting of oxygen, nitrogen, sulfur and carbon, n is 0 to 10 and y is 1 to 10. The present invention also provides a cyclic peptide comprising the amino acid sequence of NH2—X(n)—Z—X(y)—COOH and a cyclic bond between the Z residue and COOH other than a thioester bond, wherein X is selected from the group consisting of an amino acid, an amino acid analog, a peptidomimetic and a non-amide isostere, Z is selected from the group consisting of a synthetic amino acid and a biosynthetic amino acid, n is 0 to 10 and y is 1 to 10.

Abstract: The present invention relates to compositions and methods for secretion of functional proteins in a soluble form by host cells. In particular, the invention relates to membrane targeting and translocation proteins, MttA, MttB and MttC and to variants and homologs thereof. The membrane targeting and translocation proteins are useful in targeting protein expression to the periplasm of gram negative bacteria and to extracellular media of other host cells. Such expression allows secretion of expressed proteins of interest in a functional and soluble form, thus facilitating purification and increasing the yield of functional proteins of interest.

Abstract: Disclosed are Bacillus thuringiensis strains comprising novel crystal proteins which exhibit insecticidal activity against coleopteran insects including red flour beetle larvae (Tribolium castaneum) and Japanese beetle larvae (Popillia japonica). Also disclosed are novel B. thuringiensis crystal toxin genes, designated cryET33 and cryET34, which encode respectively the coleopteran-toxic proteins, CryET33 (29-kDa) crystal protein, and CryET34 (14-kDa) crystal protein. Also disclosed are methods of making and using transgenic cells comprising the novel nucleic acid sequences of the invention.

Abstract: Pleiotropic pro-inflammatory cytokines, such as TNF and IL-1, induce expression of a protein molecule, termed TSG-6, in connective tissue cells. TSG-6, or pharmaceutical compositions containing TSG-6, can be used to treat inflammatory diseases and disorders and cancer-related pathologies. Inflammatory diseases and disorders, or cancer related pathologies, can also be treated by introducing human cells transfected with a DNA molecule containing a DNA segment encoding TSG-6 protein, into humans to express therapeutically effective amounts of TSG-6 in vivo or by introducing a vector carrying a DNA segment encoding TSG-6 protein directly into humans in vivo.

Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.

Abstract: The present invention concerns muteins of avidin and streptavidin with a reduced binding affinity for biotin as well as their use as interference elimination reagents in methods for the determination of an analyte e.g. in diagnostic tests such as for example immunoassays and nucleic acid hybridization assays. In addition the invention concerns the use of muteins of avidin and streptavidin as systems capable of regeneration for binding biotin e.g. for the analysis of biotinylated molecules, for examining receptor ligand interactions as well as for the affinity purification of biotinylated molecules.

Abstract: SBHWSB2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing SBHWSB2 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Abstract: The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the polypeptide; vector derived with the DNA; host cells transformed with the vector; antibody of the polypeptide; pharmaceutical composition containing the peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the protein p140; agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylate protein p140, as active ingredient and the screening methods of the prevention and/or treatment agent. Tyrosine phosphorylation of protein p140 is an essential step in the induction of hypoglycemia by glucose uptake.